Key Highlights

  • Shares added around 11% in the session, part of a repeated pattern of outsized single-day gains through 2026
  • Full-year 2025 Revenue reached US$2.1m, up from roughly US$0.75m in 2024, ahead of guidance
  • Management cut FY26 revenue guidance from US$7.0m to US$4.5m, citing production timing rather than lost demand
  • The group closed 2025 with US$1.9m of cash against convertible Loan notes of roughly US$2.9m
  • Three customers represented more than 76% of sales, with a 48-month joint development agreement in place with a major beverage and snack group

MicroSalt's AIM-listed shares have popped again, extending a pattern of sharp swings in a thinly traded food-tech minnow. The commercial story is real, but so are the cash and dilution questions hanging over it.

A familiar jump in a lightly traded share

Shares in MicroSalt plc (LSE:SALT) moved sharply higher, adding around 11% in the session and reviving interest in one of London's more distinctive small-cap propositions: a patented salt technology that claims to deliver full flavour with far less sodium. For a company valued at only about £8m, moves of this size are not unusual, and they rarely arrive with a matching announcement.

Through 2026, MicroSalt has repeatedly registered outsized single-day gains — roughly 4% on 9 July and around 6% on 18 August, according to market commentary — without a specific regulatory news release to explain them. Coverage of those pops attributed the moves to improving sentiment toward reduced-sodium innovation and to the mechanics of a nano-cap where low Liquidity amplifies modest buying. The latest jump fits that description: there was no single announcement on the day that obviously accounts for it, and investors appear to be re-rating an accumulating body of commercial progress rather than fresh, price-sensitive news.

What MicroSalt actually does

MicroSalt's pitch is straightforward. Because conventional salt crystals are relatively large, much of the sodium in processed food passes through untasted; MicroSalt mills its salt into far smaller particles, so more is tasted per gram — letting manufacturers cut sodium while, it argues, preserving flavour. It sells both a B2B ingredient to food manufacturers and a consumer shaker product.

The B2B side is where the numbers are being made, at roughly 89% of 2025 revenue. The customer base tells you a lot about both the opportunity and the risk: three customers represented more than three-quarters of sales. Among them is a 48-month joint development agreement with what the company calls the world's largest beverage and snack group, plus a Mexican division of a major food Business placing repeat bulk orders across three countries.

The financial and operational picture

The last audited numbers showed genuine top-line momentum. Full-year 2025 revenue reached US$2.1m, up from roughly US$0.75m in 2024 and ahead of the US$2.0m guided to in January. The pre-tax loss narrowed to US$3.2m from US$5.8m, and the group even eked out a small Gross Profit of about US$87,000 against a gross loss previously; first-quarter 2026 bulk sales of US$710,000 were a record.

MicroSalt says its technology passed one billion cumulative servings in early 2026 and has broadened the range with MicroSalt Fibre and a Premium line for quick-service restaurants, with a US frozen-pizza launch flagged for mid-2026. The balance sheet, though, is where caution creeps in. The group closed 2025 with US$1.9m of cash against convertible loan notes of roughly US$2.9m, and net Assets of just US$215,000 after two raises during the year — £2.4m at 70p in February 2025 and £1.7m at 45p in December. Share count rose from 48.2m to 56.1m. Directors flagged a material uncertainty over Going Concern while expecting sufficient resources for the foreseeable future and a move to monthly cash-flow breakeven in Q4 2026.

The guidance wobble that still matters

Any assessment of the shares must reckon with the guidance reset delivered alongside the results. Having pointed to US$7.0m of 2026 revenue as recently as January, management cut the full-year figure to US$4.5m, blaming production timing tied to a 2027 launch schedule rather than any loss of demand, while reaffirming a US$15m target for 2027.

That is a meaningful downgrade — roughly a third off expected sales — and it underlines how dependent the near-term revenue line is on the production calendars of a handful of very large customers. When so much rides on when a major manufacturer schedules a reformulated product run, forecasts can slip for reasons outside MicroSalt's control, and investors buying the recovery are backing management's word that the shortfall is timing rather than substance.

What could drive the shares next

The clearest potential catalysts are commercial. Confirmation that the frozen-pizza launch and the quick-service push are converting into repeat volume, or that the 48-month joint development agreement is moving into a fuller rollout in the second half of 2026, would give the market something concrete to price — as would evidence that MicroSalt is broadening beyond its top three customers.

Reaching that Q4 2026 monthly breakeven would be a genuine inflection point, easing the funding overhang that shadows early-stage AIM stocks. The macro backdrop is supportive, with regulatory pressure on sodium and industry reformulation commitments giving the product a structural tailwind. And in a stock this illiquid, even modest buying against that narrative can move the price hard, as the year's repeated pops have shown.

Risks investors should watch

The risks are equally clear-cut. Customer concentration is the headline concern: with three customers responsible for more than 76% of sales, the slippage of any one order programme would land heavily on revenue, as the 2026 guidance cut showed. Cash is the second. A sub-£2m cash pile, convertible Debt and a history of discounted placings point to further fundraising, and any new share issuance near current levels would dilute holders — the December 2025 raise at 45p a reminder of how punitive small-cap financing can be.

Execution risk runs through everything: MicroSalt is still loss-making, still scaling and still reliant on large partners adopting its ingredient at Volume on timelines it does not control. Liquidity cuts both ways — the same thin order book that drives sharp rallies can send the shares down hard on light selling — and the company has yet to prove it can sustain profitability without leaning on the market for cash.

Investor takeaway

MicroSalt is a rare thing on AIM: a micro-cap with a credible product, fast-growing revenue and Blue-Chip food groups on its customer list. It is also a business that cut its own guidance by a third this year, carries convertible debt against a slim cash balance, leans on a handful of customers, and trades so thinly that double-digit swings say more about liquidity than fundamentals. The latest jump looks like a re-rating of an accumulating story rather than a response to any single verified catalyst.

What to monitor is specific and knowable: whether in-hand orders convert to revenue in the second half, progress toward the promised Q4 monthly breakeven, and whether the next funding round comes on terms that reward or punish current shareholders. The direction of travel on sodium reduction favours MicroSalt's (LSE:SALT) technology; whether it can turn that tailwind into self-sustaining profits before it needs the market's money again is the question the share price keeps trying, and failing, to settle.